Cyclerion Therapeutics, Inc.(NASDAQ : CYCN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.10%||162.16||0.7%||$1254.93m|
|MRK||Merck & Co., Inc.||1.03%||77.45||0.7%||$958.24m|
|BMY||Bristol-Myers Squibb Co.||1.54%||65.43||1.0%||$758.06m|
|LLY||Eli Lilly & Co.||1.76%||189.20||1.1%||$575.67m|
|RPRX||Royalty Pharma Plc||0.53%||41.87||0.2%||$143.72m|
|NVO||Novo Nordisk A/S||0.95%||72.19||0.1%||$62.10m|
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.